A neonate presented with abdominal mass in left flank was investigated and operated upon. Histopathology confirmed the diagnosis of clear cell sarcoma of the kidney. Post-operatively, chemotherapy was given according to the NWTS-5 protocol. During follow-up, the patient has shown good recovery after 7 months of surgery.
INTRODUCTION
Wilm's tumors comprise 6% to 7% of childhood cancer; whereas the remaining non-Wilm's renal tumors comprise less than l% [1] . In neonates amongst non-Wilm's tumors, most common are congenital mesoblastic nephroma (CMN), rhabdoid tumor of the kidney, and multilocular cystic nephroma, nephroblastomatosis complex & ossifying renal tumor of infancy. CCSK is most commonly observed in the age group of 3 to 5 years [2] . It is the most frequently misdiagnosed renal tumor in children, as it is unusual, has varied morphology, and there are no specific diagnostic markers [3] . Here we report a case of CCSK in a neonate.
CASE REPORT
A 28-day-old male neonate was hospitalized with progressive increasing abdominal mass for last 2 weeks. On palpation, a hard lump was noted in left flank. Ultrasound abdominal showed the mass of renal origin; there was no vascular involvement or lymphadenopathy. Routine investigations were within normal limits. Computed tomographic (CT) scan revealed left renal mass of heterogeneous nature along with cystic areas. X-ray of the chest was normal. Left nephrectomy was done and the specimen was examined histopathologically. Cord cells and spindle shaped cells interspersed in fibrovascular matrix arranged in storiform pattern were seen.
Diagnosis of clear cell sarcoma of kidney was made. Skeletal survey was done after confirmation of histology to rule out bone metastasis. Depending on histopathology report and work up for metastasis patient was found to have Stage 1 disease. Chemotherapy according to regimen I of NWTS-5 protocol was administered for 24 weeks. Patient was examined on his each hospitalization for chemotherapy schedule. There were no significant complications due to chemotherapy. Radiotherapy was not given. Contrast enhanced CT of the abdomen and pelvis was repeated. X-ray chest and skeletal survey were done after 3 and six months to rule out recurrence. There were no signs of any residual disease on follow-up. 
DISCUSSION
CCSK was first described in 1978 by three distinct groups, Beckwith and Palmer, Morgan and Kidd, and Marsden and co-workers who named it "bone metastasizing renal tumor of childhood" since it has predilection for skeletal metastasis [1] . Bone metastases occur in 40% to 60% of patients with CCSK, unlike less than 2% of patients with Wilms' tumor. Other clinical features, which separate it from Wilm's tumor, are a lack of association with sporadic aniridia and hemihypertrophy [1] . The peak incidence is between 3 and 5 years of age. It is very rare in infants younger than 6 months [4] . The present case is of a neonate. Ultrasonography is the initial investigation, which showed the mass was heterogeneous in echogenicity with cystic components and necrosis. On CT scan, non-homogeneous enhancement, with attenuation less than that of normal renal parenchyma is usually seen. Also, these tumors may contain areas of low attenuation corresponding to necrosis and cysts [5] . On cut section, these tumors appear grossly as tan-gray, soft, and mucoid. Cystic foci are almost always present and may represent the dominant feature, resembling that of multilocular renal cyst. On histopathological examination, CCSK has three components, namely, (1) There are four modalities of treatment surgical resection, surgical resection with chemotherapy, surgical resection with radiotherapy, surgical resection with chemotherapy and radiotherapy. For unexplained reasons, CCSK has been known to have the best outcome amongst all perinatal tumors [6] .
Radical nephrectomy is the initial treatment of choice if the lesion is resectable [5] . It has been found that in the NWTS-3, the addition of doxorubicin to the combination of vincristine, dactinomycin, and radiation therapy resulted in an improvement in disease-free survival in patients with clear cell sarcoma of the kidney [7] . Siebel et al found that in NWTS-4, patients treated with vincristine, doxorubicin, and dactinomycin for 15 months had an improved relapse-free survival rate compared with patients treated for 6 months (87.5% vs 60.6% at 8 y). Also, the overall survival has improved for patients with clear cell sarcoma of the kidney from NWTS-3 to NWTS-4 (83% vs 66.9% at 8 y) [8] . In the NWTS-5 protocol, CCSK is treated with radical nephrectomy followed by chemotherapy with vincristine, Doxorubicin and Etoposide for 24 weeks and radio-therapy. Overall survival is 69% [9] . Four important prognostic factors are treatment with Doxorubicin, stage of the disease, age at the time of diagnosis and presence of tumor necrosis [7] .
Emphasis should be given to look for necrosis in the radiological investigations in such cases as presence of necrosis is one of the prognostic indicators. Survival in this case can be attributed to earlier detection and lower stage of the disease at time of diagnosis.
